Kraus Carl N 4
4 · Aquestive Therapeutics, Inc. · Filed Oct 17, 2025
Insider Transaction Report
Form 4
Kraus Carl N
Chief Medical Officer
Transactions
- Sale
Common Stock
2025-10-15$7.00/sh−20,272$141,904→ 282,475 total
Footnotes (2)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
- [F2]The reported transaction involves sale transactions from $7.00 to $7.02 per share. The weighted average price per share was $7.00. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.